EGFR-directed Affibody for fluorescence-guided glioma surgery: time-dose analysis
(Conference Presentation)

Ana Luiza Ribeiro de Souza; Kayla Marra; Jason R. Gunn; Jonathan T. Elliott; Kimberley S. Samkoe; Keith D. Paulsen; Daniel R. Draney; Joachim Feldwisch

doi:10.1117/12.2212858

26 April 2016 EGFR-directed Affibody for fluorescence-guided glioma surgery: time-dose analysis (Conference Presentation)

Ana Luiza Ribeiro de Souza, Kayla Marra, Jason R. Gunn, Jonathan T. Elliott, Kimberley S. Samkoe, Keith D. Paulsen, Daniel R. Draney, Joachim Feldwisch

Author Affiliations +

Proceedings Volume 9696, Molecular-Guided Surgery: Molecules, Devices, and Applications II; 96960Q (2016) https://doi.org/10.1117/12.2212858
Event: SPIE BiOS, 2016, San Francisco, California, United States

Abstract

The key to fluorescence guided surgical oncology is the ability to create specific contrast between normal and glioma tissue. The blood brain barrier that limits the delivery of substances to the normal brain is broken in tumors, allowing accumulation of agents in the tumor interior. However, for a clinical success, imaging agents should be in the infiltrative edges to minimize the resection of normal brain while enable the removal of tumor. The aberrant overexpression and/or activation of EGFR is associated with many types of cancers, including glioblastoma and the injection of a fluorescent molecule targeted to these receptors would improve tumor contrast during fluorescence guided surgery. Affibody molecules have intentional medium affinity and high potential specificity, which are the desirable features of a good surgical imaging agent. The aim of this study was evaluate the brain/glioma uptake of ABY029 labeled with near-infrared dye IRDye800CW after intravenous injection. Rats were either inoculated with orthotopic implantations of U251 human glioma cell line or PBS (shams control) in the brain. The tumors were allowed to grow for 2–3 weeks before carrying out fluorescent tracer experiments. Fluorescent imaging of ex vivo brain slices from rats was acquired at different time points after infection of fluorescently labeled EGFR-specific affibody to verify which time provided maximal contrast tumor to normal brain. Although the tumor was most clearly visualized after 1h of IRDye800CW-labeled ABY029 injection, the tumor location could be identified from the background after 48h. These results suggest that the NIR-labeled affibody examined shows excellent potential to increase surgical visualization for confirmed EGFR positive tumors.

Conference Presentation

Citation Download Citation

Ana Luiza Ribeiro de Souza, Kayla Marra, Jason R. Gunn, Jonathan T. Elliott, Kimberley S. Samkoe, Keith D. Paulsen, Daniel R. Draney, and Joachim Feldwisch "EGFR-directed Affibody for fluorescence-guided glioma surgery: time-dose analysis (Conference Presentation)", Proc. SPIE 9696, Molecular-Guided Surgery: Molecules, Devices, and Applications II, 96960Q (26 April 2016); https://doi.org/10.1117/12.2212858

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available

Members: $17.00

Non-members: $21.00 ADD TO CART

PROCEEDINGS
PRESENTATION

WATCH
PRESENTATION SAVE TO MY LIBRARY

GET CITATION

KEYWORDS

Tumors

Brain

Surgery

Neuroimaging

Molecules

Luminescence

Visualization

Show All Keywords

Keywords/Phrases

Search In:

Publication Years